DOD Ovarian Cancer, Investigator-Initiated Research Award
ID: 358735Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358735
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award for fiscal year 2025. This grant aims to support innovative research that addresses critical needs in ovarian cancer care, with a focus on areas such as ovarian cancer biology, novel therapies, prevention strategies, early detection, and enhancing patient survivorship. The program is significant for advancing ovarian cancer research and improving care for service members and the broader community. Interested applicants can submit a pre-application by June 12, 2025, with full applications due by September 11, 2025. The estimated total program funding is $8,050,000, with individual awards up to $1.05 million for single Principal Investigators and $1.4 million for partnering PIs, and preliminary data is required to demonstrate the scientific validity of the proposed research. For further inquiries, applicants can contact the CDMRP Help Desk at 301-682-5507 or via email at help@eBRAP.org.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942525OCRPIIRA_GG.pdf
    The Department of Defense (DOD) is announcing the **Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award** for fiscal year 2025, with a funding opportunity number HT942525OCRPIIRA. This award aims to support innovative research that addresses significant needs in ovarian cancer care and has the potential for substantial contributions. Submissions are invited from both extramural and intramural organizations, including both for-profit and non-profit entities. Applications must focus on areas such as ovarian cancer biology, novel therapies, prevention strategies, early detection, and enhancing patient survivorship. Preliminary data is required to demonstrate the research's scientific validity. The application process is two-tiered: a pre-application due by June 12, 2025, followed by an invitation to submit the full application, which is due on September 11, 2025. The maximum funding for single Principal Investigators (PIs) is $1.05M, while partnering PIs can request up to $1.4M with a performance period of up to four years. Applications will undergo a rigorous peer review process assessing technical merit and programmatic relevance, with a response to funding recommendations expected by September 30, 2026. This program underlines DOD’s commitment to enhancing ovarian cancer research and care for service members and the broader community.
    Similar Opportunities
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Specialized Programs of Research Excellence (SPOREs) in Human Cancers, aimed at supporting innovative translational research from 2024 to 2026. This initiative invites applications for P50 Research Center Grants that focus on enhancing cancer prevention, early detection, diagnosis, and treatment, particularly for organ-specific cancers or related groups, with a requirement for at least one clinical trial component in each application. The program is crucial for advancing cancer research and addressing health disparities, with funding available up to $1,400,000 in direct costs per year over a five-year project period. Interested applicants can find more information and application guidelines at the NIH website and should direct inquiries to grantsinfo@nih.gov, with the application deadline set for September 25, 2026.
    Forecast to Publish a Notice of Funding Opportunity (NOFO) for NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the NCI Community Oncology Research Program (NCORP) Research Bases, which requires clinical trials. This initiative aims to enhance the generalizability and dissemination of clinical trial results by engaging cancer patient populations and organizations in rigorous studies focused on cancer control, prevention, treatment, and care delivery. The program will support seven awards with an estimated total funding of $60 million, and applications are open to small businesses. Interested applicants should note that the synopsis is expected to be posted on August 29, 2025, with a closing date for applications on November 14, 2025, and the anticipated award date is August 1, 2026. For further inquiries, contact Brandy Heckman-Stoddard, Ph.D., M.P.H., at 240-276-7048 or via email at heckmanbm@mail.nih.gov.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Human Cancers, specifically for the fiscal years 2027, 2028, and 2029, under the P50 Clinical Trial Required grant program. This initiative aims to fund innovative translational research that enhances prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups, utilizing advanced cellular, molecular, and genetic approaches. With an estimated total program funding of $25 million and the expectation of awarding 12 grants, interested applicants must submit their proposals by January 25, 2027, with the anticipated award date set for June 4, 2027. For further inquiries, applicants can contact Bradley T. Scroggins at bradley.scroggins@nih.gov or by phone at 240-276-7860.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    Novel approaches to support therapeutic development in ultra-rare cancers
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Novel approaches to support therapeutic development in ultra-rare cancers," aimed at exploring innovative methods to enhance therapeutic development for these specific cancer types. This initiative is particularly focused on small businesses, which are encouraged to apply for this cooperative agreement that falls under the discretionary category of funding. The program is significant as it addresses the critical need for advancements in treatment options for ultra-rare cancers, which often lack sufficient research and development support. Interested applicants can reach out to Patrick Johnson, Grants Management Specialist, at patrick.johnson@fda.hhs.gov or call 301-796-0154 for further information. The expected number of awards is two, with no cost-sharing requirement, and the opportunity is set for the fiscal year 2026.